VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Public ClinicalTrials.gov record NCT03556228. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 as Monotherapy and in Combination With Pembrolizumab in Subjects With Solid Tumors or Lymphoma
Study identification
- NCT ID
- NCT03556228
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- VM Oncology, LLC
- Industry
- Enrollment
- 242 participants
Conditions and interventions
Conditions
- Adenoid Cystic Carcinoma
- Any Solid Tumors Progressed After a Prior Immunotherapy
- Esophageal Cancer
- Head and Neck Cancers
- Head and Neck Cancers - Nasopharyngeal
- Head and Neck Cancers - Salivary Gland
- Head and Neck Cancers - Throat
- Head and Neck Cancers - Tonsils
- Head and Neck Cancers Hypopharynx
- Head and Neck Cancers Larynx
- Head and Neck Cancers Lip
- Head and Neck Cancers Nasopharynx
- Head and Neck Cancers Oral Cavity
- Head and Neck Cancers Oropharynx
- Head and Neck Cancers Trachea
- Head and Neck Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma HNSCC
- Lung Cancer
- Lung Cancer (Locally Advanced or Metastatic)
- Mesothelioma
- Non-Small Cell Lung Cancer
- Pancreatic Cancer
- Salivary Gland Carcinomas
- Small Cell Lung Cancer ( SCLC )
Interventions
- VMD-928 100 mg Tablet Drug
- VMD-928 Tablet and Pembrolizumab (200 mg) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 7, 2018
- Primary completion
- Nov 30, 2027
- Completion
- May 31, 2028
- Last update posted
- Dec 10, 2025
2018 – 2028
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Medical Foundation (site 209) | Santa Rosa | California | 95403 | Recruiting |
| Hartford Hospital (site 210) | Hartford | Connecticut | 06102 | Recruiting |
| The George Washington University Cancer Center (site 212) | Washington D.C. | District of Columbia | 20037 | Recruiting |
| Holy Cross Hospital (site 213) | Fort Lauderdale | Florida | 33308 | Recruiting |
| Memorial Cancer Institute at Memorial Healthcare Systems (site 132) | Pembroke Pines | Florida | 33028 | Recruiting |
| Englewood Hospital and Medical Center (site 202) | Englewood | New Jersey | 07631 | Recruiting |
| Summit Medical Group (site 205) | Florham Park | New Jersey | 07932 | Recruiting |
| Atlantic Health System, Morristown Medical Center (site 124) | Morristown | New Jersey | 07962 | Recruiting |
| Presbyterian Kaseman Hospital (site 208) | Albuquerque | New Mexico | 87110 | Recruiting |
| Weill Cornell Medicine, Cornell University (site 126) | New York | New York | 10065 | Recruiting |
| Taylor Cancer Research Center (site 204) | Maumee | Ohio | 43537 | Recruiting |
| Cancer Care Associates of York (site 206) | York | Pennsylvania | 17403 | Recruiting |
| The University of Texas MD Anderson Cancer Center (site 127) | Houston | Texas | 77030 | Recruiting |
| Utah Cancer Specialists (site 203) | Salt Lake City | Utah | 84106 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03556228, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 10, 2025 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03556228 live on ClinicalTrials.gov.